Dementia Discovery Fund
Venture capitalLondon · Seed–Series A · 80 people tracked
Investment thesis
SV Health Investors is a healthcare-focused investment firm managing multiple funds across therapeutics, biotech, healthcare growth and medtech, including the Dementia Discovery Fund.
Source: firm website, verified Jul 30, 2026.
Team · 80 people
from the firm's websiteWhat they invest in
from 11 of 11 portfolio companiesBiotech ×11Healthtech ×6Deep Tech ×4AI & Machine Learning ×2Longevity ×2Medical Devices ×2
HQs:United States×3United Kingdom×2
Investments · 11 tracked
founders shown can be your intro path
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.
BiotechDeep TechHealthtech
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)
Co-investorsForesite CapitalGV (Google Ventures)SV Life SciencesDementia DiscoveryLightstone VenturesSV Health Investors+2 more
Harness Therapeutics develops first-in-class drug candidates for neurodegenerative diseases such as Parkinson's and Huntington's disease, using its MISBA platform.
AI & Machine LearningBiotechHealthtechLongevityMedical Devices
Jan Thirkettle(CEO Director)
Co-investorsEpidarex CapitalOno Venture Investment, Inc.SV Health Investors
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)Greg Lazar(Co-Founder & Chief Scientific Officer)Richard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)
BoardAlicia Levey(Director)Michael Ross(Director)
Board seatNeil Weir· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesQiming Healthcare
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioRA CapitalLightstone VenturesOno Venture Investment, Inc.DCVC (Data Collective)
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)
Co-investorsAdvent Life SciencesNovartis Venture FundEuropean Investment FundForbionGilde HealthcareScottish Investment Bank
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)Caroline Benn(Co-founder & CSO)
Co-investorsNovartis Venture FundSV Health InvestorsForbion
Nitrase Therapeutics develops medicines based on nitrases, a class of enzymes it discovered that are involved in a range of diseases.
Biotech
Co-investorsMission BiocapitalSofinnova PartnersMission Bay Capital
NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore.
BiotechHealthtechLongevity
Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM Ventures
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsIllumina VenturesMC Healthcare VenturesHatteras Venture PartnersM VenturesPappas CapitalSV Health Investors
Sudo Biosciences discovers and develops small-molecule medicines, including next-generation TYK2 inhibitors, for serious neurological and immunological conditions such as multiple sclerosis and immune-mediated inflammatory diseases.
BiotechHealthtech
Co-investorsFrazier Life SciencesMonograph Capital PartnersSanofi Ventures
SV Health Investors is a global private equity and venture capital investment platform specializing in healthcare across biotechnology, medical devices, and healthcare growth equity.
BiotechHealthtechMedical DevicesBoston, US
Co-investorsDementia Discovery
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
LoQus23 · finance.yahoo.com · Jan 6, 2026
NRG Therapeutics · cen.acs.org · Sep 8, 2025
Frequently asked questions
- What stage does Dementia Discovery Fund invest at?
- Dementia Discovery Fund invests at the Seed, Series A stages.
- What sectors does Dementia Discovery Fund focus on?
- Dementia Discovery Fund focuses on Biotech, Digital Health, Healthtech, IoT, Medical Devices.
- Where is Dementia Discovery Fund located?
- Dementia Discovery Fund is headquartered in London, GB.
- Who does Dementia Discovery Fund co-invest with?
- Dementia Discovery Fund most often shares deals with Dementia Discovery, Lightstone Ventures, Ono Venture Investment, Inc., among 4 tracked co-investors.
Similar investors
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Elm Street Ventures is a seed and early-stage venture fund in New Haven, Connecticut that primarily backs companies with a Yale connection, especially technology developed at and licensed from Yale.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.